Trial Profile
A Multicenter, Randomized, Double-Blind, Study Comparing the Efficacy and Safety of Continuing Versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects With Non-Radiographic Axial Spondyloarthritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Non-radiographic axial spondyloarthritis; Spondylarthritis
- Focus Therapeutic Use
- Acronyms Ability-3
- Sponsors AbbVie; AbbVie Germany
- 30 May 2019 This trial has been completed in Norway, according to European Clinical Trials Database.
- 15 Mar 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 24 Oct 2018 Results assessing the Adalimumab Concentration as predictor of of achievement of sustained remission and absence of flare in Patients with Non-Radiographic Axial Spondyloarthritis, presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting